Location:
Hyatt Regency Denver at the Colorado Convention Center
650 15th St
Denver, CO 80202
Hotel Phone: (303) 436-1234
Meeting Room:
Capitol Ballroom 4-7 (Fourth Floor)
Schedule (MST):
5:30 AM – 6:00 AM — Registration and Breakfast Buffet
6:00 AM – 7:30 AM — Educational Program
There is no registration fee for these events. However, preregistration is required as seating is limited.
Faculty:
Kimberly Allman, MSN, CNP, OCN
Nurse Practitioner
Cleveland Clinic
Cleveland, Ohio
Johanna C Bendell, MD
Director, GI Oncology Research
Associate Director, Drug Development Unit
Sarah Cannon Research Institute
Nashville, Tennessee
Susan J McCall, MSN, ANP-BC
Nurse Practitioner
Memorial Sloan Kettering Cancer Center
New York, New York
Daniel P Petrylak, MD
Professor of Medicine
Director, Prostate and GU Medical Oncology
Co-Director, Signal Transduction Program
Yale Cancer Center
New Haven, Connecticut
Moderator:
Neil Love, MD
Research To Practice
Miami, Florida
Meeting space has been assigned to provide a satellite symposium supported by AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company and Merck (via educational grants) during the Oncology Nursing Society’s (ONS) 42nd Annual Congress, May 3-7, 2017 in Denver, Colorado. The Oncology Nursing Society’s assignment of meeting space does not imply product endorsement.
MODULE 1: Overview of the Clinical Role of Checkpoint Inhibitors; Biology and Pharmacology
DISCUSSION TOPICS
- Biologic rationale for immunotherapy; immune function and tumor evasion of the immune system
- Major approaches to immunotherapy
- Difference in underlying biologic mechanisms across the cancer spectrum (eg, Hodgkin lymphoma versus non-small cell lung cancer [NSCLC] versus colorectal cancer [CRC])
- Role of immune checkpoints in immunity and cancer
- Mechanism of action of checkpoint inhibitors: Anti-PD-1/PD-L1 antibodies (pembrolizumab, nivolumab, atezolizumab, durvalumab, avelumab) versus anti-CTLA-4 antibodies (ipilimumab, tremelimumab)
MODULE 2: Integration of Checkpoint Inhibitors into the Clinical Treatment Algorithm
DISCUSSION TOPICS
- Implications of integrating immunotherapy into practice for the oncology professional and clinical team
- Dosage and administration of anti-PD-1/PD-L1 antibodies; variation, if any, among diseases
- Proportion of patients who experience meaningful clinical responses to checkpoint inhibitors
- Overview of FDA approvals of anti-PD-1/PD-L1 antibodies in various diseases
- PD-L1 expression as an indicator of response to anti-PD-1/PD-L1 antibodies
- Considerations for combining anti-PD-1/PD-L1 antibodies with anti-CTLA-4 antibodies
- Determinants of treatment duration with anti-PD-1/PD-L1 antibodies
MODULE 3: Management of Immune-Related Side Effects; Contraindications to Immunotherapy; Pseudoprogression
DISCUSSION TOPICS
- Monitoring and amelioration of immunotherapy-related side effects:
- – Rash and pruritus, diarrhea and colitis, hepatic toxicity, hypophysitis and endocrinopathies, pneumonitis
- Toxicity of anti-PD-1/PD-L1 monotherapy versus combination treatment with anti-CTLA-4 antibodies
- Preexisting autoimmune conditions that constitute potential contraindications to immunotherapy (eg, Crohn’s disease, psoriasis, rheumatoid arthritis)
- Distinguishing pseudoprogression from true disease progression
MODULE 4: Emerging Strategies with Checkpoint Inhibitors; Available Clinical Trial Data in Non-FDA-Approved Settings
DISCUSSION TOPICS
- Microsatellite instability as an indicator of response to anti-PD-1/PD-L1 antibodies in CRC; data from ongoing trials evaluating checkpoint inhibitors in CRC
- Use of anti-PD-1/PD-L1 antibodies in other gastrointestinal cancers (eg, gastric cancer and hepatocellular carcinoma)
- Available safety and efficacy data with anti-PD-1/PD-L1 antibodies in patients with metastatic gynecologic cancers (eg, ovarian and endometrial cancer)
- Potential clinical role for checkpoint inhibitors in breast and prostate cancer
- Available data with the combination of checkpoint inhibitors and chemotherapy in NSCLC
- Ongoing evaluation of checkpoint inhibitors in combination with other systemic therapies (eg, VEGF inhibitors, MEK inhibitors)
Target Audience:
This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of cancer.
Learning Objectives and Goals:
Upon completion of this activity, participants should be able to:
- Recognize the FDA-approved indications for the use of immune checkpoint inhibitors in a variety of solid tumors and Hodgkin lymphoma, and identify patients for whom treatment with these agents would be appropriate.
- Describe available and emerging research evaluating the use of biomarkers or other clinical features indicative of response to immune checkpoint inhibitors, and use this information to inform treatment decision-making and/or clinical trial referral.
- Develop a plan to manage the side effects associated with immune checkpoint inhibitors to support quality of life and continuation of treatment.
- Consider the potential implications of immune checkpoint inhibition in individuals with preexisting autoimmune disorders to facilitate appropriate patient education and counseling.
- Appraise the rationale for and clinical data with investigational anti-PD-1 and anti-PD-L1 antibodies for patients with various forms of cancer.
- Recall the design of ongoing clinical trials evaluating novel immunotherapeutic approaches, alone or in combination with other systemic therapies, and counsel appropriately selected patients about availability and participation.
Accreditation Statements:
Research To Practice is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
This educational activity for 1.5 contact hours is provided by Research To Practice.
This activity is awarded 1.5 ANCC pharmacotherapeutic contact hours.
To obtain a certificate of completion and receive credit for this event, nurses must sign in at the registration desk upon arrival, attend the entire activity and return a completed Educational Assessment and Credit Form upon exiting the activity. Your certificate will be mailed to you within 4 to 6 weeks. International attendees, please note: In order for a certificate of completion to be issued, you must provide a valid email address.
ONCC/ILNA Certification Information:
The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points. Learners must apply for CNE credit to utilize this program for ONCC certification or renewal. http://www.ResearchToPractice.com/Meetings/ONS2017/ILNA
Unlabeled/Unapproved Uses Notice:
There is no implied or real endorsement of any product by Research To Practice or the American Nurses Credentialing Center. Any off-label use as declared by the FDA will be identified.
Content Validation and Disclosures:
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CNE activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
Research To Practice staff and external reviewers — The scientific staff, planners, managers and reviewers for Research To Practice have no relevant conflicts of interest to disclose.
Supporters:
This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company and Merck.
Hyatt Regency Denver at the Colorado Convention Center
650 15th Street
Denver, CO 80202
Hotel Phone: (303) 436-1234
Meeting Room:
Capitol Ballroom 4-7 (Fourth Floor)
The Hyatt Regency Denver at the Colorado Convention Center is the host hotel for the 2017 ONS Annual Congress.
Thank you for your interest in our CNE symposia series. At this time, online preregistration is closed for PART 2 – Cancer Immunotherapy session. Onsite registration will be open starting at 5:30 AM (MST) on Thursday, May 4th.
If you are interested in standing by for seating (day of the program), please visit our registration desk located outside the Capitol Ballroom 4-7, on the fourth floor of the Hyatt Regency Denver at the Colorado Convention Center hotel (650 15th St, Denver, CO 80202). You may arrive up to 30-minutes before the program start time and receive a stand by ticket.
If seats become available for the program, we will accept stand by registrations on a first come, first served basis. Please note onsite registration does not guarantee participation in the session or meal service. If you have any questions, please feel free to contact us via email atMeetings@ResearchToPractice.com or call (800) 233-6153.
|
